HLA-A and colorectal carcinoma: In the phase I study, 18 HLA‐A*2402‐positive CRC patients for whom standard therapy had failed were enrolled, and 0.5 mg, 1.0 mg, or 3.0 mg each of the peptides was mixed with incomplete Freund's adjuvant (IFA) and then s.c. injected.